Conjugated estrogens (Premarin) are most often used in the management of menopausal symptoms.

Estrogen therapy can increase the risk for breast cancer and the risk should be assessed before beginning therapy.

Blood clots are a potential consequence from the use of Premarin. Premarin can oppose the benefit of anticoagulation.

Conjugated estrogens are broken down by CYP3A4. Inhibitors may increase concentrations while inducers may reduce concentrations.